Lumito's product comprises an instrument and staining reagents based on UCNPs (up-converting nanoparticles). The instrument is intended for use in tissue diagnostics, to provide pathologists visual depictions of tissue samples as an input for making diagnosis.
The technology is patented across three global patent families that cover the creation of high-quality imaging of tissue, for instance in tumours, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on tissue diagnostics – digital pathology.
The first patent family protects the use of UCNPs for imaging in scattering materials, such as human tissue.
– Our first patent family has patents granted in key regions worldwide, and since August 2021, this also includes Europe. The patent confers a broad scope of protection, even beyond medical use. This patent is already granted in Australia, China, Israel, the United States, South Africa, Canada and Japan, says Lumito’s CEO, Mattias Lundin.
The second patent family describes the use of pulsed light to improve the efficiency of the technology and reduce the imaging time.
The third patent family protects the use of UCNPs in tissue diagnostics, the specific application area in which Lumito intends to launch its first product.
For further information, please contact
Mattias Lundin, CEO of Lumito, e-mail: ml@lumito.se.
Please also visit our website.
Lumito specializes in imaging technology within medical research and development. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers high-quality imaging of tissue, for instance in tumours, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology.
Lumito's share is traded under the ticker LUMITO on the Nordic Growth Market, NGM SME, where the Company's mentor is G&W Fondkommission, telephone: +468-503 000 50.
